News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

News|Videos|July 11, 2024

Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

Key opinion leaders share their approach to treatment sequencing for patients with multiple sclerosis (MS), taking into account comorbidities such as cardiovascular diseases, risk of infection, liver damage, and cancer as well as considering factors like planned pregnancy or advanced age.

Episodes in this series

EP. 1 Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP. 1 Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP. 2 Defining Mild Multiple Sclerosis

EP. 2 Defining Mild Multiple Sclerosis

EP. 3 Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP. 3 Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP. 4 Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP. 4 Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP. 5 Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP. 5 Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP. 6 Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP. 6 Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP. 7 De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP. 7 De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP. 8 Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP. 8 Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP. 9 Treatment Adherence in Mild Multiple Sclerosis

EP. 9 Treatment Adherence in Mild Multiple Sclerosis

EP. 10 Benign Multiple Sclerosis

EP. 10 Benign Multiple Sclerosis

EP. 11 Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP. 11 Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP. 12 Generics and Biosimilars in Multiple Sclerosis

EP. 12 Generics and Biosimilars in Multiple Sclerosis

EP. 13 Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP. 13 Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP. 14 Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

EP. 14 Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

How do you choose between different therapies for moderate MS in the context of other conditions?
- Patients with comorbidities (eg, cardiovascular diseases, risk of infection, liver damage, cancer)
- Patients considering pregnancy in the near future
- Patients who have late onset MS or are older

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease

Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy

© 2025 MJH Life Sciences^®

All rights reserved.